RMi pre-open: A fait-accompli

September 17, 2025 8:08am

A rate decision outcome, but what’s coming next, the Q is coming to a close and as I have written, the cell and gene therapy sector investors are existing in a “catalyst vacuum”?

Pre-Open Signals: 4 Positive, 1 Sell into Strength and 1 Negative indications

Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!

The market anticipates good Fed news and rises into it, but once the news is out, profits are sometimes taken…

According to Jerome, our economy now depends on a “dot plot” grid?

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

Tuesday’s night’s … RMi Closing Bell: 1 day away … https://www.regmedinvestors.com/articles/14109

RMi Research note: Sanofi (SAN-PA) has frozen R&D investment decisions in the U.K. … https://www.regmedinvestors.com/articles/14106

Wednesday: The pre-open Dow futures are UP +0.04% or (+17 points), the S&P futures are DOWN -0.06% or (-4 points) and the Nasdaq futures are DOWN -0.07% or (-18 points)

• Stock futures are mixed and barely fluctuating changed Wednesday, 9/17
• European stocks opened higher,
• Asia-Pacific markets traded higher.

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

• Tuesday: The Dow closed DOWN -125.55 points or -0.27%, the S&P closed DOWN -8.52 points or -0.13% while the Nasdaq closed DOWN -14.79 points or -0.07%
• Monday: The Dow closed UP +49.23 points or +0.11%, the S&P closed UP +30.99 points or +0.47% while the Nasdaq closed UP +207.647 points or +0.94%
• Last week, the Dow +1.56%, S&P 500 +1.63% and the Nasdaq +1.58% al gained,
• The previous week, the Dow lost -0.32%, the S&P 500 +0.33% and Nasdaq gained +1.14%.

Economic Data Docket: more than a few …

• FOMC Rate Decision (4%-4.25% expected, 4.25%-4.5% previously);
• MBA mortgage applications, week ending Sept. 12 (+9.2% previously);
• Housing starts, August (1.37 million expected, 1.42 million previously);
• Building permits preliminary reading, August (1.37 million expected, 1.36 million previously); Housing starts, month-on-month, August (-3.7% expected, +5.2% previously);
• Building permits, month-on-month, August (+0.6% expected, -2.2% previously)

Q3 – September, 1 holiday, 5 negative and 6 positive closes

• August - 11 negative and 9 positive closes
• July – 1 market holiday, 13 positive and 9 negative closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• Let ‘em ride, I see an econ laden session – I see less red versus green as September continues to close the Q, along with the usual ups, downs and just plain uncertainties

Although:

CRISPR Therapeutics (CRSP) closed up +$3.35 after Monday’s +$1.58, Friday’s +$0.37, Thursday’s +$4.08 and last Wednesday’s -$1.88 with a positive +$0.19 or +0.16% pre-open – Sell into Strength

BioNTech SE (BNTX) closed up +$1.38 after Monday’s +$1.14, Friday’s -$7.57, Thursday’s +$3.31 and last Wednesday’s -$1.09, following the previous Tuesday’s -$0.57 and Monday’s -$9.80 with a positive +$0.49 or+-0.26% pre-open

Moderna (MRNA) closed up +$0.96 after Monday’s +$0.37, Friday’s -$1.88 and Thursday’s +$1.08 with a positive +$0.06 or +0.24% pre-open

Solid Biosciences (SLDB) closed down -$0.08 after Monday’s +$0.10 and Friday’s +$0.08 with a negative -$0.01 or -0.18% pre-open

Vertex Pharmaceuticals (VRTX) closed down -$1.85 after Monday’s -$1.12, Friday’s -$3.04, Thursday’s +$8.82 and last Wednesday’s -$7.93 following the previous Tuesday’s +$1.23 and last Monday’s -$0.87 with a positive +$1.50 or +0.38% pre-open

IQV Holdings (IQV) closed up +$0.84 after Monday’s -$1.25, Friday’s -$3.47, Thursday’s +$6.77 and last Wednesday’s -$5.77 following the previous Tuesday’s +$1.99 with a positive +$0.49 or +0.26% pre-open

The BOTTOM LINE: The big unknown for investors?

A key question for investors this week is whether Fed officials push back against market bets on a series of interest-rate cuts extending into next year.

• A quarter-point reduction is seen as a sure thing when the Fed announces its policy decision Wednesday, with a small potential for a half-point move amid signs that US job growth is slowing rapidly. But markets have also priced in reductions continuing deep into 2026 to ward off a recession. <P. Serafino, Bloomberg>

Interesting stat, retail sales defied weak sentiment …

• Beyond the Fed, the calendar brings a weekly update on jobless claims and fresh manufacturing data, offers supplementary signals on the strength of the economy.

September is in the front window: understand the “flow”

• 9/16 – Tuesday closed positive with 29 positive, 9 negative and 2 flats
• 9/15 – Monday closed negative with 17 positive, 22 negative and 1 flat

Q2 Earnings are in the rear-view mirror; 4 net incomes and 25 net losses of 29 releases; however we are  about to start again …!

I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

Welcome to my world of defining the “grey’ in our universe!

• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.